Literature DB >> 24887695

Specific tumor labeling enhanced by polyethylene glycol linkage of near infrared dyes conjugated to a chimeric anti-carcinoembryonic antigen antibody in a nude mouse model of human pancreatic cancer.

Ali A Maawy1, Yukihiko Hiroshima2, Yong Zhang3, George A Luiken4, Robert M Hoffman5, Michael Bouvet6.   

Abstract

Labeling of metastatic tumors can aid in their staging and resection of cancer. Near infrared (NIR) dyes have been used in the clinic for tumor labeling. However, there can be a nonspecific uptake of dye by the liver, lungs, and lymph nodes, which hinders detection of metastasis. In order to overcome these problems, we have used two NIR dyes (DyLight 650 and 750) conjugated to a chimeric anti-carcinoembryonic antigen antibody to evaluate how polyethylene glycol linkage (PEGylation) can improve specific tumor labeling in a nude mouse model of human pancreatic cancer. The conjugated PEGylated and non-PEGylated DyLight 650 and 750 dyes were injected intravenously into non-tumor-bearing nude mice. Serum samples were collected at various time points in order to determine serum concentrations and elimination kinetics. Conjugated PEGylated dyes had significantly higher serum dye concentrations than non-PEGylated dyes (p=0.005 for the 650 dyes and p<0.001 for the 750 dyes). Human pancreatic tumors subcutaneously implanted into nude mice were labeled with antibody-dye conjugates and serially imaged. Labeling with conjugated PEGylated dyes resulted in significantly brighter tumors compared to the non-PEGylated dyes (p<0.001 for the 650 dyes; p=0.01 for 750 dyes). PEGylation of the NIR dyes also decreased their accumulation in lymph nodes, liver, and lung. These results demonstrate enhanced selective tumor labeling by PEGylation of dyes conjugated to a tumor-specific antibody, suggesting their future clinical use in fluorescence-guided surgery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24887695      PMCID: PMC4160999          DOI: 10.1117/1.JBO.19.10.101504

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  22 in total

1.  Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.

Authors:  Hiroyuki Kishimoto; Yasuo Urata; Noriaki Tanaka; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

2.  Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer.

Authors:  Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet
Journal:  Hepatogastroenterology       Date:  2012-09

3.  Comparison of a chimeric anti-carcinoembryonic antigen antibody conjugated with visible or near-infrared fluorescent dyes for imaging pancreatic cancer in orthotopic nude mouse models.

Authors:  Ali A Maawy; Yukihiko Hiroshima; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet
Journal:  J Biomed Opt       Date:  2013-12       Impact factor: 3.170

4.  Glowing tumors make for better detection and resection.

Authors:  Michael Bouvet; Robert M Hoffman
Journal:  Sci Transl Med       Date:  2011-11-23       Impact factor: 17.956

5.  Fluorescence-guided surgery of human colon cancer increases complete resection resulting in cures in an orthotopic nude mouse model.

Authors:  Cristina A Metildi; Sharmeela Kaushal; Cynthia S Snyder; Robert M Hoffman; Michael Bouvet
Journal:  J Surg Res       Date:  2012-09-07       Impact factor: 2.192

Review 6.  PEGylated antibodies and antibody fragments for improved therapy: a review.

Authors:  Andrew P Chapman
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

Review 7.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

8.  Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer.

Authors:  Cristina A Metildi; Sharmeela Kaushal; Minya Pu; Karen A Messer; George A Luiken; Abdool R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  Ann Surg Oncol       Date:  2014-02-06       Impact factor: 5.344

9.  In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody.

Authors:  Cristina A Metildi; Chih-Min Tang; Sharmeela Kaushal; Stephanie Y Leonard; Paolo Magistri; Hop S Tran Cao; Robert M Hoffman; Michael Bouvet; Jason K Sicklick
Journal:  Ann Surg Oncol       Date:  2013-08-14       Impact factor: 5.344

10.  Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice.

Authors:  Yukihiko Hiroshima; Ali Maawy; Sho Sato; Takashi Murakami; Fuminari Uehara; Shinji Miwa; Shuya Yano; Masashi Momiyama; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  J Surg Res       Date:  2013-11-19       Impact factor: 2.192

View more
  6 in total

1.  Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore.

Authors:  Thinzar M Lwin; Takashi Murakami; Kentaro Miyake; Paul J Yazaki; John E Shivley; Robert M Hoffman; Michael Bouvet
Journal:  Ann Surg Oncol       Date:  2018-01-25       Impact factor: 5.344

Review 2.  Current status and future perspectives of fluorescence-guided surgery for cancer.

Authors:  Jonathan C DeLong; Robert M Hoffman; Michael Bouvet
Journal:  Expert Rev Anticancer Ther       Date:  2015-12-07       Impact factor: 4.512

3.  Fluorescence-guided surgery of retroperitoneal-implanted human fibrosarcoma in nude mice delays or eliminates tumor recurrence and increases survival compared to bright-light surgery.

Authors:  Fuminari Uehara; Yukihiko Hiroshima; Shinji Miwa; Yasunori Tome; Shuya Yano; Mako Yamamoto; Yasunori Matsumoto; Hiroki Maehara; Kazuhiro Tanaka; Michael Bouvet; Fuminori Kanaya; Robert M Hoffman
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

Review 4.  Molecular Imaging of Pancreatic Cancer with Antibodies.

Authors:  Christopher G England; Reinier Hernandez; Savo Bou Zein Eddine; Weibo Cai
Journal:  Mol Pharm       Date:  2015-12-10       Impact factor: 4.939

5.  Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.

Authors:  Steve Knutson; Erum Raja; Ryan Bomgarden; Marie Nlend; Aoshuang Chen; Ramaswamy Kalyanasundaram; Surbhi Desai
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

Review 6.  The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review.

Authors:  Michael A Turner; Thinzar M Lwin; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Paul J Yazaki; Michael Bouvet
Journal:  Biomolecules       Date:  2021-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.